The purpose of our study was to develop a multigene signature based on transcriptome profiles of both mRNAs and lncRNAs to identify a group of patients who are at high risk of early relapse in stages II-III colon cancer. Firstly, propensity score matching was conducted between patients in early relapse group and long-term survival group from GSE39582 training series (N = 359) and patients were matched 1:1. Global transcriptome analysis was then performed between the paired groups to identify tumor specific mRNAs and lncRNAs. Finally, using LASSO Cox regression model, we built a multigene early relapse classifier incorporating 15 mRNAs and three lncRNAs. The prognostic and predictive accuracy of the signature was internally validated in 102 colon cancer patients and externally validated in other 241 patients. In the training set, patients with high risk score were more likely to suffer from relapse than those with low risk score (HR: 2.67, 95% CI: 2.07-3.46, P < 0.001). The results were validated in the internal validation set (HR: 2.23, 95% CI: 1.23-3.78, P = 0.003) and external validation (HR 1.88, 95% CI 1.42-2.48; P < 0.001) set. Time-dependent receiver operating curve at 1 year showed that the integrated mRNA-lncRNA signature [area under curve (AUC) = 0.742] had better prognostic accuracy than AJCC TNM stage (AUC = 0.615) in the entire 702 patients. In addition, survival decision curve analyses at 12 months revealed a good clinical usefulness of the integrated mRNA-lncRNA signature. In conclusion, we successfully developed an integrated mRNA-lncRNA signature that can accurately predict early relapse.
Introduction
Colorectal cancer (CRC) is globally one of the most common type of cancer and also a major cause of cancer-related deaths (1) . In spite of the advances in screening, diagnosis, curative resection and adjuvant therapy, recurrence or metastasis following surgery is still a major and ultimate cause of deaths for colon cancer patients. It is reported that about 40-50% of cases would develop relapse after curative primary resection with one-third being local recurrence and two-thirds distant metastasis (2) (3) (4) . In most cases, the relapse of colon cancer can be characterized as a process with time sequence. Approximately 50% of relapse occurred within the first year after initial primary resection, nearly 90% of relapse cases emerged within the first 3 years (5-7). Early relapse in colon cancer patients is attributed mainly to poor clinicopathological features such as advanced tumor stage, poor differentiation and malignant histopathological type and resistance to adjuvant chemotherapy. The past clinical studies have revealed consistent trend of poor survival rates in cases who developed early relapse. Consequently, more accurate strategies are warranted to be applied to help detect early relapse.
Currently, treatment selection is mainly based on the American Joint Commission on Cancer/International Union against Cancer (AJCC/UICC) tumor-node metastasis (TNM) staging system which is the most significant risk factor for predicting early relapse in colon cancer (8) . Though a variety of clinicopathological features can be incorporated with tumor stage to improve survival prediction for colon cancer, prognosis always varies significantly in colon cancer patients even with the same tumor stage and comparable clinicopathological features. These problems have prompted the search for more ideal biomarkers to predict early relapse of colon cancer (9) (10) (11) . In recent years, with the development of high-throughput technologies, many studies have focused on gene expression profiles in colon cancer and several multigene signatures have been developed to predict the prognosis of colon cancer patients (12) (13) (14) (15) (16) . However, very few molecular prognostic classifiers have been established to detect early relapse in colon cancer. More importantly, no previous study has combined mRNA and long non-coding (lncRNA) to construct a signature to predict the early relapse of colon cancer. This kind of novel signature based on the transcriptome profiles of both mRNAs and lncRNAs have been suggested to be a better classifier in predicting survival outcome of breast cancer patients (17, 18) . As a critical part of non-coding RNAs, lncRNAs have been extensively confirmed to have an important role in predicting survival outcome in colon cancer (19) (20) (21) . Thus identifying a group of powerful mRNAs and lncRNAs for early relapse prediction is of great clinical significance.
In this study, we aimed to develop and validate a multigene signature for the prediction of early relapse by analyzing the transcriptome profiles including both mRNAs and lncRNAs. We believed that the signature integrating more transcript information would improve risk stratification and provide a more accurate assessment of individual treatment in stages II-III colon cancer.
Materials and methods

Preprocessing of transcriptome microarray
Raw microarray cell intensity (CEL) files of colon cancer were obtained from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih. gov/geo/) and were background-adjusted and normalized using Robust Multichip Average (22) . All data were under the same chip platform (Affymetrix Human Genome U133 Plus 2.0 chips). All probes were mapped to the latest version of the NetAffx Annotation File. When multiple probes were mapped to the same EntrezGeneID, the mean value was used to represent its average expression level. The ComBat method was used to remove the potential internal and external batch effects.
Selection of colon cancer datasets
All datasets meeting the following criteria were identified: (i) all datasets were created by Affymetrix HG-U133 plus 2.0 platform; (ii) basic clinical information and follow-up information of relapse free survival (RFS) and status should be available among all sets; (iii) sample size of sets were limited to over one hundred to increase the credibility of data analyzing. Datasets missing necessary clinicopathological or follow-up data were excluded. Finally, CRC datasets of GSE39582, GSE14333, GSE17536 and GES37892 were recruited. However, previous studies have found that there was extensive overlap between samples in the GSE17536 and GSE14333 series by analyzing their probe CEL files (23) . In addition, considering the staging system of samples in GSE14333 was Duke's staging method, we finally excluded GSE14333 dataset. All the cases in datasets were further filtered based on the criteria of stages II-III colon cancer with complete clinicopathological and follow up information. As the biggest set, GSE39582 consists of 461 stage II-III colon cancer, and hence, it was assigned to a training and an internal validation series. GSE17536 and GSE37892 were combined and set as external validation series.
Identification of early relapse associated mRNAs and lncRNAs
Early relapse was defined as the locoregional recurrence or distant metastasis between 3 months and 1 year after initial primary resection (10) . Relapse cases within 3 months were not deemed as early relapse to avoid the confounding bias of potential synchronous metastases (24) .
Patients in training set from GSE39582 were identified and separated into early relapse group and long-term survival group (no relapse after a minimum of 5 years follow-up). The propensity score (PS) is defined as the conditional probability of treatment given background variables, and hence, it has widely been used to reduce selection bias by equating groups based some critical covariates (25) . Therefore, PS matching analysis was performed between the two groups (long-term survival vs. early relapse) in our study adjusting for tumor stage, location and adjuvant chemotherapy. Matched ratio was set as 1:1. Finally, 34 paired patients in the training series were selected to perform transcriptome profiling. Linear Models for Microarray data (LIMMA) method was used to generate the differentially expressed mRNAs and lncRNAs between early relapse and long-term survival samples (26) . We selected the differentially expressed mRNAs (fold change >1.5, P < 0.05). The thresholds for differentially expressed lncRNAs were as follows: fold change >1.25 and P < 0.05. Because of the incomplete nomenclature of lncRNAs, we focused on those lncRNAs by HUGO gene nomenclature committee (HGNC) (http://www.genenames. org/). Lastly, LASSO Cox regression model (27) was conducted to select the most useful mRNAs and lncRNAs from all the differentially expressed genes associated with early relapse. 
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Development of risk score and statistical analysis
Using LASSO Cox regression model, we identified a list of mRNAs and lncRNAs and constructed a multi-RNA-based classifier for predicting the early relapse of stage II-III patients in the training set. A standard formula of risk score for each patient was calculated combining the expression levels of the RNAs and LASSO Cox regression coefficients. Patients from different sets were divided into high-risk and low-risk groups by using the median risk score of the training set as the cutoff point. Kaplan-Meier estimator was used to compare the survival differences for patients in training, internal validation and external validation set between high risk and low risk group. Multivariable Cox regression analysis and data stratification analysis were adopted to test the independent role of risk score in predicting RFS. Time-dependent receiver operating characteristic (ROC) analysis was used to investigate the prognostic or predictive accuracy of each feature and signature. Survival decision curve analysis (DCA) was used to evaluate the net benefit derived from the integrated mRNA-lncRNA signature. Decision curve analysis examined the theoretical relationship between the threshold survival probability at 1 year of colon cancer and the relative value of false-positive and false-negative results to determine the value of the prediction model (28) . All statistical analyses were performed using of R (version 3.25.0, www.r-project.org). All statistical tests were two-sided, and P < 0.05 were considered statistically significant.
Results
Preparation of colon cancer data sets
A total of 702 patients were identified and comprehensively studied, which included 461 patients from GSE39582 (359 patients from the training set and 102 from the internal validation set), 111 patients from GSE17536 and 130 patients from GSE37892. The raw clinical information of all patients can be found in Supplementary Table 1, available at Carcinogenesis Online.
Development of early relapse signature from the training series
To begin with, patients in training set were divided into early relapse group and long-term survival group. Patients' baseline features before and after PS matching analysis were showed in Table 1 . Before PS analysis, patients in early relapse group have significantly higher T and N stage. After PS matching, no significant differences can be found between the two groups among age, AJCC stage, tumor location and adjuvant chemotherapy variables (Table 1 ). Transcriptome change profiling was then performed between early relapse and long-term survival groups. Thirty-eight genes (30 mRNAs and 8 lncRNAs) were differentially expressed between the two groups ( Figure 1A) . LASSO coefficient profiles of the 38 RNAs were shown in Figure 1B . A coefficient profile plot was produced against the log (λ) sequence. Vertical line was drawn at the value selected using 10-fold cross-validation, and the minimize λ method resulted in 15 mRNAs and three lncRNAs. The detailed fold change and P value of these 38 genes were provided in Table S2 . Risk score was lastly calculated for every patient in training set based on the expression levels of the 18 RNAs and LASSO Cox regression coefficients: The prognostic value of integrated mRNA-lncRNA signature in training, internal validation and external validation series
By applying the median risk score as cutoff value, patients in training set were separated into low-risk group (N = 179) and high-risk group (N = 180). The distribution of risk scores and relapse status was shown in Figure 2A (left panel), which suggested that patients with lower risk scores generally had better RFS than those with higher risk scores. Time-dependent ROC analyses at 1, 3 and 5 years were conducted to assess the prognostic accuracy of the integrated mRNA-lncRNA signature ( Figure 2A , middle panel). The RFS rates for patients in low-risk group were 96.0% at 1 year, 87.8% at 3 year, and 85.0% at 5 year, compared with 78.0%, 58.8%, and 55.6% in patients in highrisk group, respectively (HR: 2.93, 95% CI: 1.95-4.42, P = 0.026, Figure 2A , right panel).
The same analyses were then conducted in the internal validation set. In the internal validation series, 1, 3 and 5-year RFS rates were 93.0, 81.0 and 81.0% for the low-risk group, and 85.6, 61.2 and 59.1% for the low-risk group (HR 2.51, 95% CI 1.12-5.63, P = 0.026, Figure 2B) .
To confirm the similar prognostic value of the integrated mRNA-lncRNA classifier in different populations, we combined the samples in GSE17536 and GSE37892 and a total of 241 colon cancer patients were further studied for the validation. Using the established cutoff point, 76 (31.5%) patients were classified as high risk, and 165 (68.5%) as low risk. 1-year disease-free survival was 85.0% for the high-risk group and 95.0% for the lowrisk group (HR 3.09, 95% CI 1.50-6.34; P = 0.002; Figure 2C ).
In the entire dataset analysis, risk score-based classification yielded similar results ( Figure 2D ). Colon cancer patients can be categorized into low and high risk patients with significantly different RFS and the signature showed the highest predictive accuracy at one year after surgery.
Independence and prognostic performance of the signature in predicting early relapse
After multivariate analysis adjusted by clinicopathological variables, the integrated mRNA-lncRNA classifier remained a powerful and independent factor in the training, internal validation and external validation series (Table 2) . Subgroup analysis based on stage KRAS mutation status and adjuvant chemotherapy suggested that high-risk patients in each subgroup were inclined to have significantly unfavorable RFS (Figure 3) . Samples from the entire dataset were then separated into five risk groups based on their relapse free status and time: group A (relapse within 1 year), group B (relapse within 3 years), group C (relapse after 3 year), group D (no relapse within 5 year), group E (no relapse after minimum 5 years). The distribution of risk score among the five groups were showed in Supplementary Figure 1 , available at Carcinogenesis Online. As expected, group A showed the highest risk score, while group E showed the lowest.
To certify that integrated mRNA-lncRNA signature perform more accurately in predicting early relapse in all patients, timedependent ROC was used and it was suggested that integrated mRNA-lncRNA signature [area under curve (AUC) = 0.742] had significantly higher prognostic accuracy than tumor stage (AUC = 0.615) at 1 year ( Figure 4A ).
Clinical use of the integrated mRNA-lncRNA signature
The DCA at 1 year for the integrated mRNA-lncRNA signature, tumor stage and that for the signature with AJCC tumor stage integrated was presented in Figure 4B . The decision curve showed that if the threshold probability is >5%, using the integrated signature to predict early relapse added more benefit than either the treat-all-patients scheme or the treat-none scheme, while the tumor stage never brought any benefit. Within this range, net benefit was comparable, with several overlaps, on the basis of the integrated mRNA-lncRNA signature and the signature with tumor stage integrated.
Exploratory validation in RNA sequencing-based database
With the rapid development of RNA sequencing (RNA-Seq), a technology enabling rapid profiling and deep investigation of the transcriptome, it has witnessed an increasing adoption of RNA-Seq technology by researchers. Therefore, we made an exploratory validation in the dataset from The Cancer Genome mRNA-lncRNA signature was constructed based on the 15 mRNAs and three lncRNAs identified in GEO database. The basic information of TCGA stages II-III colon cancer patients was described in Supplementary Table 3, available that it played an important role in detecting early postoperative relapse in stages II/III colon cancer patients. More recently, our study group for the first time paid attention to global mRNAs profiling and its involvement in the prediction of early relapse in stages I-III colon cancer (16) . Although bearing great novelty in analyzing and predicting early relapse, our previous study was not designed perfect enough. First of all, stage I patients were not excluded. By comprehensively reanalyzing our data, we found that stage I patients had only two relapses and yet this was used as the baseline for univariate and multivariate analysis, which may increase the bias when making mRNAs profiling. Secondly, we neglected the impact of potential synchronous metastases.
Though it is still controversial about the determination of time point of synchronous metastases, we believe taking this factor into consideration would help to improve analyzing accuracy for our study. Thirdly, the clinical practicality of signature was not well evaluated. Most importantly, our previous study focused only on mRNAs, not integrating the critical transcriptome information of lncRNAs. With increasingly awareness of these limitations, we re-analyzed all the data and conducted a new study.
In this study, a novel prognostic classifier based on 15 mRNAs and three lncRNAs were developed to improve the prediction of early relapse after surgical resection. By applying the integrated mRNA-lncRNA signature to the GSE39582 training set, a clear separation was observed in the survival curves between low and high-risk patients. And it was internally validated in the validation set of GSE39582 patients and the external cohorts of GSE17536 and GSE37892, indicating a broad applicability of this signature in colon cancer. Stratified by AJCC stage, the integrated mRNAs-lncRNAs signature remains a good prognostic model, implying that the mRNA signature can be used to refining the current staging system. Time-dependent ROC at 1 year suggested that this signature has the most significant accuracy in predicting tumor relapse within the first year after initial resection of colon cancer. Furthermore, survival DCA curve at 12 months revealed a great clinical practicality. Therefore, our study identified a robust integrated mRNAs-lncRNAs signature that could help identify patients with high risk of early relapse and guide individualized treatment of patients with colon cancer, which is of incredible value to clinical application. Further exploratory validation analysis in TCGA confirmed the great significance of the 15 mRNAs and three lncRNAs identified in our study.
Most genes included in the signature have been experimentally demonstrated to be linked with cancer. Of these, nine mRNAs including ATOH1, CXCL10, EGR3, GZMB, HSD17B2, INHBB, KLK11, PTPRT and SPINK1 have been previously reported to have a prognostic role in colon cancer. ATOH1 is the basic helix-loophelix transcription factor. Its expression regulated by Notch receptor signaling pathway will determine cell fate in the intestine. What's more, it is required for the differentiation of all secretory cells and functions as an important tumor suppressor in human CRCs (32) . CXCL10 was small cytokines belonging to the CXC chemokine family. Previous studies have confirmed that it can inhibit angiogenesis selectively via the chemokine receptor CXCR3-B (33) . EGR3 is an immediate-early growth response gene which is induced by mitogenic stimulation and it has been proved to be significantly correlated with 5-fluorouracil resistance in colon cancer (34) . GZMB is a serine protease expressed by cytotoxic T lymphocytes and natural killer cells (35) . Patients with low expression of GZMB have been proved to have poor disease free survival (36) . HSD17B2, an enzyme catalyzing opposite reaction of estrogen metabolism, has been previously suggested to be negatively associated with prognosis in CRC (37) . As a subunit of both activin and inhibin, the overexpression of INHBB has been proved to be correlated with poor RFS (38) . KLK11 is homologue to KLK3 and encodes the prostatespecific antigen which is a widely used biomarker for the detection and monitoring of prostate cancer (39) . A lot of clinical and basic studies have confirmed that KLK11 mRNA expression predicts poor disease-free and overall survival, knockdown of it will inhibit cell proliferation in human CRC (40) (41) (42) . Protein tyrosine phosphatase receptor-like genes including PTPRR is a member of superfamily of tumor suppressors in CRC (43) . Previous high-throughput gene expression analysis found that the transcription was markedly decreased in CRC tumors (44) . SPINK1, also known as pancreatic secretory trypsin inhibitor and tumor-associated trypsin inhibitor, is mainly produced in the acinar cells of the exocrine pancreas. It was suggested that serum levels of SPINK1 can independently predict poor prognosis in CRC patients (45) and the its protein expression level was significantly linked with liver metastasis (46) . However, its mRNA expression level was firstly revealed to be associated with prolonged RFS in our study. Therefore, the potential mechanism for the inconsistent prognostic value between mRNA expression level and protein level of SPINK1 needs further studies. Of the three identified lncRNAs, only SNHG17 has been reported in only one study in CRC (47) . As for the rest six mRNAs and two antisense lncRNAs integrated in our signature, further clinical and basic research should be conducted to explore their significance in colon cancer.
To date, several multi-gene assays like Oncotype DX (48), ColoPrint (49) and ColDX (50) have been developed in the hope of aiding in decision making with regard to implement of adjuvant therapy in stages II-III colon cancer patients. However, before the signature constructed in our study can be established as clinical-grade assay, further steps are needed according to the established guidelines (51): firstly, identification of an appropriate approach to quantifying expression (microarray); secondly, design of specific probes based on the sequences tested in the microarray chips; thirdly, validation in independent cohorts of patients with complete clinical information. We will validate the prognostic value of this signature in our cancer center.
Inevitably, several innate limitations are still existed in our study. Firstly, our study was based on the data from a public available dataset without testing in a prospective clinical trial. Furthermore, the information of several other important clinicopathological features, like differentiation and number of lymph nodes, was not available in the training set. Finally, the biological functions of the mRNAs and lncRNAs incorporated in the integrated signature are still needed to be further explored.
Conclusions
In conclusion, we successfully developed an integrated mRNAlncRNA signature that can accurately identify a group of patients who are at high risk of early relapse in stages II-III colon cancer. Future prospective clinical trials are needed to verify the clinical significance of this integrated mRNA-lncRNA signature in detecting postoperative early relapse in colon cancer patients.
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